Genomic assays are increasingly used in oncology to guide clinical management and assess tumor responsiveness to novel therapeutics. As the number of cancer genes with clinical relevance expands, broader mutational profiling will be necessary. Here we present the analytical validation of the ACE Cancer Panel, the largest gene panel currently available for clinical use.
